<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498951</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00011601</org_study_id>
    <secondary_id>NCI-2015-01014</secondary_id>
    <secondary_id>ML29496</secondary_id>
    <secondary_id>IRB00011601</secondary_id>
    <secondary_id>R01CA137488</secondary_id>
    <nct_id>NCT02498951</nct_id>
  </id_info>
  <brief_title>Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response</brief_title>
  <official_title>Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well obinutuzumab works as maintenance treatment&#xD;
      in patients with central nervous system lymphoma who have achieved the disappearance of all&#xD;
      signs of cancer in response to treatment (complete response) or a decrease in the size of a&#xD;
      tumor, or in the extent of cancer in the body, in response to treatment (partial response).&#xD;
      Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere&#xD;
      with the ability of tumor cells to grow and spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the effect of maintenance obinutuzumab on duration of response (partial&#xD;
      response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central&#xD;
      nervous system lymphoma (PCNSL) who attain PR or CR to first-line treatment with high-dose&#xD;
      methotrexate-based chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate overall survival after PR or CR (overall survival [OS]-PRCR). II. To evaluate&#xD;
      neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.&#xD;
&#xD;
      III. Progression-free survival (PFS) and overall survival (OS) will be calculated.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2&#xD;
      for the first cycle, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for&#xD;
      2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II (OBSERVATION): Patients undergo observation for a total of 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial response (PR) or complete response (CR) duration</measure>
    <time_frame>From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years</time_frame>
    <description>PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) after CR</measure>
    <time_frame>From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years</time_frame>
    <description>OS after PR or CR will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be measured by the Wechsler Adult Intelligence Scale, Hopkins Verbal Learning Test-Revised, and Grooved Pegboard Test. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 and Brain Cancer Module-20. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years</time_frame>
    <description>PFS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start date of first-line PCNSL treatment to death, assessed up to 2 years</time_frame>
    <description>OS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Central Nervous System B-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (obinutuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (observation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo observation for a total of 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (obinutuzumab)</arm_group_label>
    <arm_group_label>Arm II (observation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (obinutuzumab)</arm_group_label>
    <other_name>Anti-CD20 Monoclonal Antibody R7159</other_name>
    <other_name>GA-101</other_name>
    <other_name>GA101</other_name>
    <other_name>Gazyva</other_name>
    <other_name>huMAB(CD20)</other_name>
    <other_name>R7159</other_name>
    <other_name>RO 5072759</other_name>
    <other_name>RO-5072759</other_name>
    <other_name>RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (obinutuzumab)</arm_group_label>
    <arm_group_label>Arm II (observation)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of&#xD;
             diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid&#xD;
             (CSF); diagnosis must be documented by pathology report&#xD;
&#xD;
          -  Must have undergone first-line treatment with a high-dose methotrexate-based&#xD;
             chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is&#xD;
             defined as &gt;= 3 grams/m^2; methotrexate dose reduction for creatinine clearance &lt; 100&#xD;
             ml/min is permitted&#xD;
&#xD;
          -  Must be within 75 days of completion of first-line treatment regimen; must have&#xD;
             achieved objective response (PR or CR/unconfirmed complete response [CRu]) to&#xD;
             first-line treatment&#xD;
&#xD;
          -  Brain magnetic resonance imaging (MRI) documenting objective response must be obtained&#xD;
             within 30 days of study enrollment&#xD;
&#xD;
          -  If CSF was positive for lymphoma cells at diagnosis or during first-line treatment&#xD;
             and/or a slit lamp examination was positive at diagnosis or during first-line&#xD;
             treatment, then the CSF and vitreal studies must have been repeated and must have&#xD;
             indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities&#xD;
             on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or&#xD;
             during first-line treatment and/or slit lamp examination was positive at diagnosis or&#xD;
             during first-line treatment, then the CSF and vitreal studies must have been repeated&#xD;
             and must have indicated CR; for CRu, some patients will have a small but persistent&#xD;
             enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often&#xD;
             difficult to ascertain whether this represents a residual nidus of tumor or scar&#xD;
             tissue; if the abnormality does not change or slowly involutes without therapy and&#xD;
             corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is&#xD;
             determined, the patient should not have used corticosteroids for at least two weeks&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 60; Eastern Cooperative Oncology Group (ECOG) 0,&#xD;
             1, or 2&#xD;
&#xD;
          -  Signed informed consent form (ICF)&#xD;
&#xD;
          -  Ability and willingness to comply with the requirements of the study protocol&#xD;
&#xD;
          -  Total bilirubin &lt; 3 x the upper limit of normal (ULN), +/- 7 days from date of ICF&#xD;
             signing&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min (calculated according to institutional standards or&#xD;
             using Cockcroft-Gault formula), +/- 7 days from date of ICF signing&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 5 x ULN, +/- 7&#xD;
             days from date of ICF signing&#xD;
&#xD;
          -  Platelet &gt;= 75,000 cells/mm^3, +/- 7 days from date of ICF signing&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL, +/- 7 days from date of ICF signing&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1.5 x 10^3 cells/mm^3, +/- 7 days from date of ICF signing&#xD;
&#xD;
          -  Surgically sterile or agree to use effective contraception using an adequate measure&#xD;
             of contraception such as oral contraceptives, intrauterine device, or barrier method&#xD;
             of contraception in conjunction with spermicidal jelly while receiving obinutuzumab&#xD;
             and &gt;= 18 months after the last dose of obinutuzumab for women, and 180 days after the&#xD;
             last dose of obinutuzumab for men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy&#xD;
&#xD;
          -  Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin&#xD;
             lymphoma&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  History of other malignancy that could affect compliance with the protocol or&#xD;
             interpretation of results&#xD;
&#xD;
               -  Patients with a history of curatively treated basal or squamous cell carcinoma of&#xD;
                  the skin or in situ carcinoma of the cervix are generally eligible; patients with&#xD;
                  a malignancy that has been treated, but not with curative intent, will also be&#xD;
                  excluded, unless the malignancy has been in remission without treatment for &gt;= 2&#xD;
                  years prior to enrollment&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding&#xD;
             fungal infections of nail beds) or any major episode of infection requiring treatment&#xD;
             with IV antibiotics or hospitalization (related to the completion of the course of&#xD;
             antibiotics) within 4 weeks prior to study enrollment&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to study enrollment&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Known positive hepatitis serologies:&#xD;
&#xD;
               -  Hepatitis B (HBV): patients with positive serology for hepatitis B defined as&#xD;
                  positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody&#xD;
                  (anti-HBc); patients who are positive for anti-HBc may be considered for&#xD;
                  inclusion in the study on a case-by-case basis if they are hepatitis B viral&#xD;
                  deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA&#xD;
                  testing by real-time polymerase chain reaction (PCR); patients with positive&#xD;
                  serology may be referred to a hepatologist or gastroenterologist for appropriate&#xD;
                  monitoring and management&#xD;
&#xD;
               -  Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV&#xD;
                  ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion&#xD;
                  in the study on a case-by-case basis&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Ambady</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas E. Ney</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Douglas E. Ney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin M. Dunbar</last_name>
      <phone>470-572-3111</phone>
      <email>erin.dunbar@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Erin M. Dunbar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry R. Junck</last_name>
      <phone>800-865-1125</phone>
      <email>ljunck@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Larry R. Junck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy E. Strowd</last_name>
      <phone>336-713-5440</phone>
      <email>rstrowd@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Roy E. Strowd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Peereboom</last_name>
      <phone>216-445-6068</phone>
      <email>peerebd@ccf.org</email>
    </contact>
    <investigator>
      <last_name>David M. Peereboom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prakash Ambady</last_name>
      <phone>503-494-5626</phone>
      <email>ambady@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash Ambady</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Glantz</last_name>
      <email>mjg@massmed.org</email>
    </contact>
    <investigator>
      <last_name>Michael J. Glantz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Barth</last_name>
      <phone>401-444-8559</phone>
      <email>peter.barth@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Peter Barth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa A. Thomas</last_name>
      <phone>802-656-9427</phone>
      <email>Alissa.thomas@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Alissa A. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schiff</last_name>
      <phone>434-924-5610</phone>
      <email>DS4JD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Schiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Prakash Ambady</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

